Organon (OGN) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 30.1% versus a loss of 9.5%. Over five years, VKTX leads with a +374.9% price change compared with -60.5% for OGN. Organon is the larger company by market cap ($3.61 billion vs $3.53 billion), about 1.0 times the size.
Organon pays a dividend yielding 0.58%, while Viking Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | VKTX |
|---|---|---|
| Share price | $13.75 | $27.73 |
| Market cap | $3.61B | $3.53B |
| 1-day change | -0.29% | -2.84% |
| YTD return | +92.33% | -18.87% |
| 1-year return | +30.09% | -9.50% |
| 5-year return | -60.48% | +374.88% |
| P/E ratio (TTM) | 17.63 | — |
| Forward P/E | 3.80 | — |
| EPS (TTM) | $0.78 | $-4.67 |
| Dividend yield | 0.58% | 0.00% |
| Annual dividend | $0.08 | $0.00 |
| Revenue (latest FY) | $6.22B | $0 |
| Revenue growth (YoY) | -2.92% | — |
| Net income (latest FY) | $187.00M | $-359.64M |
| Gross margin | 53.30% | — |
| Net margin | 3.01% | — |
| 52-week high | $13.80 | $43.15 |
| 52-week low | $5.69 | $25.77 |
| Distance from 52-week high | -0.36% | -35.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -18.18% | +241.54% |
| Average volume | 2.64M | 4.02M |
| Shares outstanding | 262.61M | 127.17M |
| Employees | 10,000 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed VKTX by 39.6 percentage points over the past year.
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
OGN vs VKTX FAQ
Which is bigger, Organon or Viking Therapeutics?
Organon (OGN) is larger, with a market capitalization of $3.61B compared with $3.53B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, OGN or VKTX?
OGN returned +30.09% over the past 12 months, compared with -9.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Organon or Viking Therapeutics?
Organon pays a dividend yielding 0.58%, while Viking Therapeutics does not currently pay a regular dividend.
Are Organon and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.